Using the Clinical Practice Research Datalink, adults diagnosed with T2DM newly initiated with a basal long/intermediate-acting insulin from January 2004 to December 2016 were identified. First change or add on of short or premix insulin and/or OADs was defined as intensification. Patients were categorized into three groups; uncontrolled glycaemia at baseline (≥7% HbA1c) and early (within 1-year) intensifiers, and uncontrolled glycaemia at baseline and delayed (>1-year) intensifiers and uncontrolled-non-intensifiers as a reference groups. A total of n=8,538 patients were included; 32.95% (n=2,813) were uncontrolled-glycaemic-early intensifiers, 28.91% (n=2,468) were uncontrolled glycaemic-delayed intensifiers, and 38.15% (n=3,257) were non-intensifiers. Majority of the early and delayed intensified patients were males (54.60% and 57.41% respectively) and the average age was 62.40years. Non-intensifiers were older (67.72 years) and had a greater number of risk factors. Median baseline HbA1c was 85.90mmol/mol [10.01%] (IQR, 73.9-101.0 mmol/mol; 8.91-11.39%) and 82.50mmol/mol [9.70%] (IQR, 71.60-96.70mmol/mol, 8.70-11.00%) in the early and delayed treatment intensified group respectively. Early treatment intensification within 1-year post basal insulin therapy was linked to 18% (HR CI: 0.65, 1.03), 23% (HR CI: 0.58, 1.02) and 28% (HR CI: 0.58, 0.93) reduction in the risk of HF, MI and stroke respectively. CVE risk was also reduced in the delayed versus non-intensified group.

In conclusion, large proportion of patients remain non-intensified post basal insulin despite poor glycemic control, timely intensification in primary care is thus central in minimising CVE complications.

Disclosure

M. Adan: None. S. Seidu: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Servier. Board Member; Self; Novartis Pharmaceuticals Corporation, Novo Nordisk Inc. Research Support; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Sanofi-Aventis. Speaker’s Bureau; Self; Amgen, Lilly Diabetes, Merck Sharp & Dohme Corp. K. Khunti: Advisory Panel; Self; Amgen, AstraZeneca, Bayer AG, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Menarini Group, Merck Sharp & Dohme Corp., Napp Pharmaceuticals, Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi-Aventis, Servier. Board Member; Self; AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis. Consultant; Self; Amgen, AstraZeneca, Bayer AG, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Menarini Group, Merck Sharp & Dohme Corp., Napp Pharmaceuticals, Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi-Aventis, Servier. Research Support; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi-Aventis, Servier. Speaker’s Bureau; Self; Amgen, AstraZeneca, Bayer AG, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Menarini Group, Merck Sharp & Dohme Corp., Napp Pharmaceuticals, Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi-Aventis, Servier. F. Zaccardi: Speaker’s Bureau; Self; Napp Pharmaceuticals. C.L. Gillies: None. R. Lubwama: Employee; Self; Sanofi US. A.H. Boss: Employee; Self; Sanofi. Stock/Shareholder; Self; Novo Nordisk Inc., Sanofi. T.A. Dex: Consultant; Self; Sanofi US. Stock/Shareholder; Self; Bayer Healthcare Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.